Next Science hit by Covid-19 shutdowns

Wound care technology developer Next Science was hit by shutdowns of elective surgeries and wound care clinics in the United States during the first six months of 2020, curbing revenue. Sales for the six months were $1.9 million, a small reduction on the previous corresponding period. Sales of Bactisure wound wash, BlastX anti-microbial wound gel…

Immuron reveals anti-Covid potential, raises $28 million

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors. On Tuesday the company reported its Travelan product for the prevention of travellers’ diarrhoea demonstrated neutralising activity against severe acute respiratory syndrome coronovirus-2, the virus that causes…